BREAST
L
UNG
PROSTATE
BLADDER
NON-HODGKIN’S
LYMPHOMA
KIDNEY & RENAL
PELVIS
COLON & RECTAL
THYROID
MELANOMA
OTHER
Tania Stutman’s doctor
was tactful but blunt: She had one year to live. The cancer
in her small bowel, he explained, was rare and untreatable. “Go home and get your af-
fairs in order,” he said, Stutman recalls. That was in 1998. But Stutman, 49 at the time,
defied the odds. She survived her gastrointestinal tumor for the next three years, long
enough to take part in a clinical trial of a pioneering new drug called Gleevec. Within
two months of starting the drug, Stutman saw her tumor shrink by 50 percent. She’s
C1
C2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
C3
C4
Zoom level
fit page
fit width
A
A
fullscreen
one page
two pages
share
print
clip
SlideShow
fullscreen
Open Article
article text for page
< previous story
|
next story >
add comment
|
read comments
Share this page with a friend
Save to “My Stuff”
Subscribe to this magazine
Search
Help
